Pathophysiology of major depression by clinical stages

dc.contributor.authorGalvão, Ana Cecília de Menezes
dc.contributor.authorAlmeida, Raíssa Nobrega
dc.contributor.authorSousa Júnior, Geovan Menezes de
dc.contributor.authorMiguel, Mario André Leocadio
dc.contributor.authorFontes, Fernanda Palhano Xavier de
dc.contributor.authorAraujo, Draulio Barros de
dc.contributor.authorSoares, Bruno Lobão
dc.contributor.authorOliveira, João Paulo Maia de
dc.contributor.authorNunes, Emerson Arcoverde
dc.contributor.authorHallak, Jaime Eduardo Cecilio
dc.contributor.authorSchuch, Felipe Barreto
dc.contributor.authorSarris, Jerome
dc.contributor.authorGalvão-Coelho, Nicole Leite
dc.date.accessioned2021-08-09T11:47:59Z
dc.date.available2021-08-09T11:47:59Z
dc.date.issued2021-08-05
dc.description.resumoThe comprehension of the pathophysiology of the major depressive disorder (MDD) is essential to the strengthening of precision psychiatry. In order to determine the relationship between the pathophysiology of the MDD and its clinical progression, analyzed by severity of the depressive symptoms and sleep quality, we conducted a study assessing different peripheral molecular biomarkers, including the levels of plasma C-reactive protein (CRP), serum mature brain-derived neurotrophic factor (mBDNF), serum cortisol (SC), and salivary cortisol awakening response (CAR), of patients with MDD (n = 58) and a control group of healthy volunteers (n = 62). Patients with the first episode of MDD (n = 30) had significantly higher levels of CAR and SC than controls (n = 32) and similar levels of mBDNF of controls. Patients with treatment-resistant depression (TRD, n = 28) presented significantly lower levels of SC and CAR, and higher levels of mBDNF and CRP than controls (n = 30). An increased severity of depressive symptoms and worse sleep quality were correlated with levels low of SC and CAR, and with high levels of mBDNF. These results point out a strong relationship between the stages clinical of MDD and changes in a range of relevant biological markers. This can assist in the development of precision psychiatry and future research on the biological tests for depressionpt_BR
dc.identifier.citationGALVÃO, Ana Cecília de Menezes; ALMEIDA, Raíssa Nobrega; SOUSA, Geovan Menezes de; LEOCADIO-MIGUEL, Mario André; PALHANO-FONTES, Fernanda; ARAUJO, Dráulio Barros de; LOBÃO-SOARES, Bruno; MAIA-DE-OLIVEIRA, João Paulo; NUNES, Emerson Arcoverde; HALLAK, Jaime Eduardo Cecilio. Pathophysiology of Major Depression by Clinical Stages. Frontiers In Psychology, [S.l.], v. 12, p. 641779, ago. 2021. Doi: http://dx.doi.org/10.3389/fpsyg.2021.641779. Disponível em: https://www.frontiersin.org/articles/10.3389/fpsyg.2021.641779/full. Acesso em: 5 ago. 2021.pt_BR
dc.identifier.doi10.3389/fpsyg.2021.641779
dc.identifier.urihttps://repositorio.ufrn.br/handle/123456789/33046
dc.languageenpt_BR
dc.publisherFrontiers Media SApt_BR
dc.rightsAttribution 3.0 Brazil*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/br/*
dc.subjectCortisolpt_BR
dc.subjectC-reactive proteinpt_BR
dc.subjectBrain-derived neurotrophic factorpt_BR
dc.subjectSleep qualitypt_BR
dc.subjectPrecision psychiatrypt_BR
dc.titlePathophysiology of major depression by clinical stagespt_BR
dc.typearticlept_BR

Arquivos

Pacote Original

Agora exibindo 1 - 1 de 1
Nenhuma Miniatura disponível
Nome:
PathophysiologyMajorDepression_Araujo_2021.pdf
Tamanho:
2.01 MB
Formato:
Adobe Portable Document Format
Descrição:
PathophysiologyMajorDepression_Araujo_2021
Nenhuma Miniatura disponível
Baixar

Licença do Pacote

Agora exibindo 1 - 1 de 1
Nenhuma Miniatura disponível
Nome:
license.txt
Tamanho:
1.53 KB
Formato:
Item-specific license agreed upon to submission
Nenhuma Miniatura disponível
Baixar